Myomo reports Q2 results
- Co reports Q2 (Jun) loss of $(3.35) per share; revenue grew 21% YoY to $0.31 mln. There are no analyst estimates.
- In the US, MyoPro is currently available to veterans at Veterans Administration hospitals across the country and in over 30 O&P practice locations. After recently achieving the CE Mark, co now looks forward to launching outside the U.S. The initial introduction of MyoPro is planned for Germany through its distributor partner, Ottobock, a well-established German-based technical O&P global leader.
No comments:
Post a Comment